Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

IN8bio, Inc. INAB

Healthcare  —  Biotechnology
1.20 0.01 0.84% as of 25 Sep
Market cap
$11.1M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

IN8bio, Inc. (INAB) Business Profile

Updated before January 2025

Company Overview

IN8bio, Inc. (NASDAQ: INAB) is a biotechnology company focused on developing innovative therapies in the field of cancer treatment. Founded in 2016, IN8bio is headquartered in New York City, New York. The company specializes in the development of gamma-delta T cell therapies, a novel approach to immunotherapy that leverages the unique properties of gamma-delta T cells to target and destroy cancer cells. IN8bio was co-founded by Dr. William Ho, who currently serves as the Chief Executive Officer, and has assembled a team of experienced professionals in oncology, immunology, and cell therapy development. The company went public in 2021, raising capital to accelerate its research and development efforts.

Core Business Segments

Gamma-Delta T Cell Therapies

IN8bio’s primary focus is on the development of gamma-delta T cell therapies, which represent a promising new frontier in cancer treatment. These therapies are designed to harness the natural ability of gamma-delta T cells to recognize and kill cancer cells while sparing healthy tissue. The company’s pipeline includes:

  • INB-200: A gamma-delta T cell therapy targeting glioblastoma, an aggressive form of brain cancer. INB-200 is currently in clinical trials and has shown promising early results.
  • INB-100: A therapy designed to prevent relapse in patients undergoing hematopoietic stem cell transplantation for leukemia. This product is also in clinical development.
  • Preclinical Programs: IN8bio is actively exploring additional indications for its gamma-delta T cell platform, including solid tumors and other hematologic malignancies.

Research and Development Services

In addition to its proprietary therapies, IN8bio provides research and development services to academic institutions and pharmaceutical companies. These services include preclinical testing, cell therapy manufacturing, and regulatory support.

Business Model

IN8bio operates on a hybrid business model that combines proprietary product development with collaborative partnerships. The company generates revenue through:

  1. Clinical Development: Advancing its pipeline of gamma-delta T cell therapies through clinical trials and eventual commercialization.
  2. Collaborations and Licensing: Partnering with academic institutions and pharmaceutical companies to co-develop therapies or license its technology.
  3. Grants and Funding: Securing non-dilutive funding from government agencies and private foundations to support its research efforts.

This diversified approach allows IN8bio to mitigate risks associated with drug development while maximizing its impact in the field of oncology.

Strategic Direction

IN8bio is committed to advancing the field of gamma-delta T cell therapy and expanding its pipeline to address unmet medical needs. Key strategic priorities include:

  • Pipeline Expansion: Developing new indications for its gamma-delta T cell platform, including additional solid tumors and hematologic malignancies.
  • Global Reach: Establishing partnerships with international organizations to bring its therapies to patients worldwide.
  • Sustainability Goals: Implementing environmentally friendly practices in its manufacturing and research operations.
  • Innovation: Investing in cutting-edge technologies to enhance the efficacy and safety of its therapies.

Competitive Landscape

IN8bio operates in a highly competitive environment, with several companies pursuing similar approaches to cancer immunotherapy. Key competitors include:

  • Adaptimmune Therapeutics: Focused on T-cell receptor therapies for solid tumors.
  • Kite Pharma (a Gilead Company): A leader in CAR-T cell therapies for hematologic cancers.
  • Fate Therapeutics: Specializes in off-the-shelf cell therapies, including natural killer (NK) cells and T cells.
  • Immunocore: Develops T-cell receptor-based therapies for cancer and infectious diseases.

Despite the competition, IN8bio differentiates itself through its focus on gamma-delta T cells, which offer unique advantages in terms of safety and efficacy.

Risk Factors

Like any biotechnology company, IN8bio faces several risks that could impact its business:

  • Clinical Trial Risks: The success of IN8bio’s therapies depends on positive clinical trial results, which are inherently uncertain.
  • Regulatory Challenges: Obtaining regulatory approval for new therapies is a complex and time-consuming process.
  • Market Dependence: The company’s revenue is heavily reliant on the success of its gamma-delta T cell platform.
  • Supply Chain Disruptions: Manufacturing cell therapies requires specialized materials and equipment, which could be affected by global supply chain issues.
  • Competition: The biotechnology sector is highly competitive, and new advancements by competitors could impact IN8bio’s market position.

Recent Developments

IN8bio has made significant progress in recent months, including:

  • Clinical Trial Updates: Positive interim results from the Phase 1 trial of INB-200 for glioblastoma, demonstrating safety and preliminary efficacy.
  • Partnerships: A collaboration with a leading academic institution to explore new applications for gamma-delta T cell therapy.
  • Corporate Milestones: Expansion of its manufacturing capabilities to support late-stage clinical trials and commercialization.
  • Global Developments: The COVID-19 pandemic has highlighted the importance of resilient supply chains, prompting IN8bio to invest in supply chain optimization.

Investment Considerations

Strengths

  • Innovative Platform: IN8bio’s focus on gamma-delta T cells sets it apart from competitors.
  • Strong Leadership: Experienced management team with a proven track record in oncology and cell therapy.
  • Growing Pipeline: Multiple clinical and preclinical programs targeting high-value indications.
  • Collaborative Approach: Partnerships with academic institutions and pharmaceutical companies enhance its R&D capabilities.

Risks

  • Early-Stage Company: IN8bio is still in the clinical development phase and has not yet commercialized any products.
  • High R&D Costs: Developing cell therapies is expensive, and the company may require additional funding.
  • Regulatory Uncertainty: Approval timelines and requirements can vary, impacting the commercialization of its therapies.

Conclusion

IN8bio, Inc. is a pioneering biotechnology company at the forefront of gamma-delta T cell therapy development. With a robust pipeline, strong leadership, and a commitment to innovation, the company is well-positioned to address unmet medical needs in oncology. While it faces challenges typical of early-stage biotech companies, its unique approach and strategic partnerships provide a solid foundation for future growth. Investors should weigh the company’s strengths and risks carefully, but IN8bio’s potential to revolutionize cancer treatment makes it a compelling opportunity in the biotechnology sector.